Clinical Trial Update: A Prospective, Single-Arm, Single-Center Phase II Study Evaluating the Efficacy and Safety of Chidamide Combined With PD-L1 Inhibitor, Carboplatin, and Etoposide as First-Line Treatment in Patients With Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) [Phase 2]

View source ↗

Summary

A prospective, single-arm Phase II trial is evaluating the safety and efficacy of adding chidamide to a PD-L1 inhibitor, carboplatin, and etoposide as first-lin…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Small Cell Lung Cancer

Drugs mentioned

• CARBOPLATIN (Carboplatin)
• Chidamide (chidamide)
• Etoposide (Etoposide)
• PD-L1 inhibitor (Programmed death-ligand 1 inhibitor)

Snippet

Sponsor: China Medical University, China | Conditions: Small Cell Lung Cancer | Phase 2 | Status: RECRUITING